Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $57.71 Consensus PT from Analysts

Posted by on Aug 23rd, 2026

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) have earned an average rating of “Buy” from the sixteen brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and four have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $58.7692.

Several brokerages recently weighed in on SRRK. Citigroup upped their target price on shares of Scholar Rock from $58.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wedbush reissued an “outperform” rating and issued a $64.00 price target on shares of Scholar Rock in a research report on Friday. JPMorgan Chase & Co. boosted their price target on shares of Scholar Rock from $56.00 to $63.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. BMO Capital Markets reaffirmed an “outperform” rating and set a $76.00 price objective on shares of Scholar Rock in a research report on Friday, August 7th. Finally, Barclays increased their price objective on Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, May 8th.

Get Our Latest Research Report on Scholar Rock

Insider Activity

In other news, Director Michael Gilman sold 2,544 shares of Scholar Rock stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the transaction, the director owned 59,511 shares in the company, valued at approximately $3,205,857.57. This trade represents a 4.10% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katie Peng sold 5,446 shares of Scholar Rock stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $293,430.48. Following the completion of the transaction, the director owned 34,301 shares of the company’s stock, valued at $1,848,137.88. The trade was a 13.70% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 17,149 shares of company stock worth $923,108 over the last three months. Company insiders own 10.30% of the company’s stock.

Institutional Trading of Scholar Rock

Hedge funds have recently added to or reduced their stakes in the company. Syon Capital LLC increased its position in shares of Scholar Rock by 6.4% in the 2nd quarter. Syon Capital LLC now owns 9,782 shares of the company’s stock valued at $538,000 after purchasing an additional 588 shares during the last quarter. Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock during the 2nd quarter worth $4,834,000. Senator Investment Group LP acquired a new position in shares of Scholar Rock during the second quarter worth $11,275,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Scholar Rock during the second quarter worth $232,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Scholar Rock by 8.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 111,186 shares of the company’s stock worth $6,115,000 after purchasing an additional 8,274 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Performance

NASDAQ SRRK opened at $56.50 on Thursday. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02. The company has a market cap of $6.88 billion, a P/E ratio of -16.38 and a beta of 0.69. The stock has a 50-day moving average of $51.86 and a two-hundred day moving average of $48.48. Scholar Rock has a 1-year low of $27.07 and a 1-year high of $58.49.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.84). During the same quarter last year, the firm posted ($0.98) EPS. As a group, analysts anticipate that Scholar Rock will post -3.23 EPS for the current year.

Scholar Rock Company Profile

(Get Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

Featured Stories

Analyst Recommendations for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.